Selected article for: "clinical trial and human vaccine"

Author: Zou, Jing; Xie, Xuping; Fontes-Garfias, Camila R.; Swanson, Kena A.; Kanevsky, Isis; Tompkins, Kristin; Cutler, Mark; Cooper, David; Dormitzer, Philip R.; Shi, Pei-Yong
Title: The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization
  • Cord-id: dzlg3os1
  • Document date: 2021_3_25
  • ID: dzlg3os1
    Snippet: Initial COVID-19 vaccine candidates were based on the original sequence of SARS-CoV-2. However, the virus has since accumulated mutations, among which the spike D614G is dominant in circulating virus, raising questions about potential virus escape from vaccine-elicited immunity. Here, we report that the D614G mutation modestly reduced (1.7–2.4-fold) SARS-CoV-2 neutralization by BNT162b2 vaccine-elicited mouse, rhesus, and human sera, concurring with the 95% vaccine efficacy observed in clinica
    Document: Initial COVID-19 vaccine candidates were based on the original sequence of SARS-CoV-2. However, the virus has since accumulated mutations, among which the spike D614G is dominant in circulating virus, raising questions about potential virus escape from vaccine-elicited immunity. Here, we report that the D614G mutation modestly reduced (1.7–2.4-fold) SARS-CoV-2 neutralization by BNT162b2 vaccine-elicited mouse, rhesus, and human sera, concurring with the 95% vaccine efficacy observed in clinical trial.

    Search related documents:
    Co phrase search for related documents
    • Try single phrases listed below for: 1